Terminated PHASE2 INTERVENTIONAL 2-arm NCT04811924

The Effect of Mitomycin C on Corneal Haze and Scarring After Corneal Crosslinking in Keratoconus Patients

Sponsor: Ciusss de L'Est de l'Île de Montréal

Interventions Application of 0.02% MMC over 60 seconds post corneal crosslinking. Corneal crosslinking without the application of 0.02% MMC

Updated 7 times since 2021 Last updated: Feb 27, 2023 Started: Jul 26, 2021 Primary completion: Feb 22, 2023 Completion: Feb 22, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Change in methodolody.

Other terminated trials from Ciusss de L'Est de l'Île de Montréal

See all terminations from Ciusss de L'Est de l'Île de Montréal

Other Keratoconus trials with similar outcome

Browse all Keratoconus trials

Listed as NCT04811924, this PHASE2 trial focuses on Keratoconus and remains terminated or withdrawn. Sponsored by Ciusss de L'Est de l'Île de Montréal, it has been updated 7 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Mar 2023 — Jul 2024 [monthly]

Terminated PHASE2

Status: Recruiting → Terminated
Nov 2021 — Mar 2023 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting

▶ Show 2 earlier versions

Oct 2021 — Nov 2021 [monthly]

Not Yet Recruiting PHASE2
Apr 2021 — Oct 2021 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ciusss de L'Est de l'Île de Montréal

Data source: Ciusss de L'Est de l'Île de Montréal

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Montreal, Canada